Last updated: July 27, 2026
Executive summary
The matter captioned AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC, Case No. 1:15-cv-01139, is a federal patent case filed in the District of New Jersey. The litigation’s procedural posture and core issues track standard Hatch-Waxman dynamics, with AstraZeneca asserting that Amneal’s proposed generic application infringes one or more Orange Book-listed AstraZeneca patents tied to an FDA-approved branded product. This produces two direct business impacts: (1) a near-term exclusivity and launch-delay pathway for AstraZeneca during the litigation and any settlement, and (2) a remaining launch and design-around risk profile for Amneal based on claim scope (independent claim breadth), remaining asserted patents, and any adjudication or covenant terms.
Litigation specifics (case identifiers, parties, venue, docket)
- Case title: AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC
- Case number: 1:15-cv-01139
- Court: U.S. District Court for the District of New Jersey
- Parties:
- Plaintiff: AstraZeneca Pharmaceuticals LP
- Defendant: Amneal Pharmaceuticals LLC
- Type of dispute: Patent infringement tied to FDA-regulated generic entry (Hatch-Waxman framework implied by parties’ typical enforcement pattern and the 2015 filing context; docket-level details drive what is actually asserted).
Important note for precision: A complete litigation claim-by-claim summary requires the patent list, claim construction decisions, and the parties’ briefing record (complaint, infringement contentions, claim construction order, summary judgment order, and any final judgment or settlement). Those case documents are not provided in the prompt.
What patents did AstraZeneca assert against Amneal in 1:15-cv-01139?
Featured snippet answer: The specific asserted patents and asserted claims are not identifiable from the case caption and docket number alone in the information provided.
How Hatch-Waxman typically maps this lawsuit
In cases of this pattern, AstraZeneca’s asserted estate typically includes:
- Drug substance and/or drug product patents listed in the Orange Book for the brand.
- Method-of-use patents tied to FDA-approved indications or dosing regimens.
- Formulation or manufacturing patents where the generic’s product profile is alleged to fall within claim limitations.
Key documents that determine which patents were asserted
A claim-level map depends on:
- The complaint (lists asserted patent numbers and theories).
- Infringement contentions (maps accused product(s) to claim elements).
- The Markman/claim construction order (fixes claim interpretations that decide infringement.
What claims did Amneal challenge, and how did AstraZeneca respond?
Featured snippet answer: The record of invalidity defenses (anticipation/obviousness/indefiniteness/§101 if asserted) and AstraZeneca’s replies are not available from the case identifier alone.
Invalidity angles commonly raised in Hatch-Waxman
For the 2015-era patent landscape, typical defenses include:
- 35 U.S.C. §102/§103 (anticipation/obviousness) against prior art references.
- Indefiniteness (35 U.S.C. §112(b)) where claim boundaries are disputed.
- Non-infringement based on differences in generic composition, dosage form, or method steps.
- In some cases, §101 eligibility is raised for specific patent categories.
Litigation mechanics that change outcomes
Business-critical turning points usually are:
- Claim construction narrowing or broadening.
- Summary judgment rulings on infringement and/or invalidity.
- The status of any remaining asserted patents after partial dismissals or stipulations.
What was the procedural timeline for AstraZeneca v. Amneal (1:15-cv-01139)?
Featured snippet answer: A dated timeline (complaint filing, initial case management, claim construction, dispositive motions, trial/settlement) is not determinable from the provided information.
Milestones that drive launch-delay and settlement economics
A decision-quality timeline includes:
- Filing date of the complaint and service.
- Early deadlines for invalidity/infringement contentions.
- Claim construction schedule.
- Summary judgment briefing and rulings.
- Status of any stipulation of non-infringement or dismissal.
- Final resolution: judgment, dismissal with prejudice, or settlement terms.
How strong was AstraZeneca’s patent position in this case?
Featured snippet answer: Strength cannot be quantified without the asserted patent numbers, claim construction results, and any dispositive rulings.
How litigators assess “strength” in a Hatch-Waxman case
In practice, strength depends on:
- Claim construction outcomes (how strictly the generic must match the asserted elements).
- Prior art positioning (whether the key novelty is narrow or robust).
- The posture after dispositive motions (invalidity findings reduce settlement leverage).
- Whether AstraZeneca preserved multiple independent claims across multiple patents.
Did the court issue claim construction or dispositive rulings in 1:15-cv-01139?
Featured snippet answer: The existence, content, and effect of any claim construction and summary judgment orders cannot be stated from the prompt.
Why claim construction matters for generic launch
Generic infringement is often a binary consequence of:
- A narrow construction that requires exact element correspondence.
- A broad construction that makes design-around harder.
What settlement terms or covenants typically accompany resolution of a case like this?
Featured snippet answer: Settlement/covenant terms are not provided, so the launch timelines and permitted launch dates cannot be derived.
Standard Hatch-Waxman settlement economics
Common settlement structures include:
- Launch date for the generic.
- Design-around rights (a modified formulation or process that avoids infringement).
- Payment-for-delay components (if present, they create separate litigation and scrutiny).
- Ongoing dispute over remaining patents or continued litigation against additional ANDA applicants.
How does this lawsuit affect the Orange Book status and exclusivity for the branded drug?
Featured snippet answer: Orange Book listings for the implicated brand cannot be identified from the case caption alone.
What to check for a complete Orange Book tie-out
A full Orange Book tie requires:
- The brand’s NDA holder and listing set.
- Patent number list and status (expired, expiring, delisted, amended).
- Orange Book “exclusivity” codes (data exclusivity, 5-year, 3-year, pediatric extension) for the NDA.
What generic entry risks exist for Amneal after 1:15-cv-01139?
Featured snippet answer: Post-resolution risk depends on which patents remain and whether the generic can design around. Those specifics are not available from the provided prompt.
Launch risk matrix (what determines “risk,” once patents are known)
Once asserted patents are listed, entry risk typically breaks into:
- Remaining asserted patent scope (composition vs method vs manufacturing).
- Injunction exposure (common if AstraZeneca wins on at least one independent claim).
- Design-around feasibility (whether claim elements can be avoided).
- Regulatory lag (labeling changes, updated samples, CMC comparability).
How does AstraZeneca’s estate in this case compare with other Orange Book estates?
Featured snippet answer: Without asserted patent numbers, a comparative strength analysis against other estates is not feasible.
Benchmark metrics used by investors and licensing teams
- Number of independent claims across asserted patents.
- Breadth after claim construction.
- Number of remaining patents at settlement/judgment.
- Court’s view of invalidity and infringement (orders and rationale).
Key takeaways
- Case identified: AstraZeneca Pharmaceuticals LP v. Amneal Pharmaceuticals LLC, 1:15-cv-01139, in the District of New Jersey.
- Business impact pathway: Standard Hatch-Waxman dynamics imply AstraZeneca asserted Orange Book patents to delay/stop Amneal’s generic entry.
- Missing for an outcome-grade summary: The prompt does not include the asserted patent numbers, the claims, or any court orders/settlement documents, so the litigation’s substantive merits and practical launch implications cannot be stated precisely.
FAQs
- What information in the complaint identifies the asserted AstraZeneca patents in 1:15-cv-01139?
- Do claim construction rulings typically decide infringement in AstraZeneca v. Amneal-style Hatch-Waxman cases?
- What docket entries confirm whether the case ended by settlement or judgment?
- How do remaining asserted patents after partial dismissal affect generic launch timing?
- Which Orange Book codes (3-year/5-year/pediatric) usually control exclusivity once patent litigation ends?
References (APA)
No sources were provided in the prompt, and no case docket documents were included.
